Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
about
Advancements in the development of subunit influenza vaccinesBinding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometryEvaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011-2012 influenza seasonComparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors.Identification of the source of A (H10N8) virus causing human infection.Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) VirusesDetection and Genetic Characteristics of H9N2 Avian Influenza Viruses from Live Poultry Markets in Hunan Province, ChinaRapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR.Does pandemic A/H1N1 virus have the potential to become more pathogenic?The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.Influenza virus resistance to neuraminidase inhibitors: implications for treatment.Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses.Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.Nosocomial outbreak of the pandemic Influenza A (H1N1) 2009 in critical hematologic patients during seasonal influenza 2010-2011: detection of oseltamivir resistant variant viruses.Phylogenetic and antigenic characterization of reassortant H9N2 avian influenza viruses isolated from wild waterfowl in the East Dongting Lake wetland in 2011-2012.Glycan based detection and drug susceptibility of influenza virus.Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.New treatments for influenzaIdentification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screeningStructural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289KCharacteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication.Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases.Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategiesInfluenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.Oseltamivir-resistant influenza A 2009 H1N1 virus in immunocompromised patients.In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity.An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistanceZanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.Oseltamivir Dosing in Critically Ill Patients With Severe Influenza.Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus.Discovery of Potent Neuraminidase Inhibitors Using a Combination of Pharmacophore-Based Virtual Screening and Molecular Simulation Approach.Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.Deep Sequencing of H7N9 Influenza A Viruses from 16 Infected Patients from 2013 to 2015 in Shanghai Reveals Genetic Diversity and Antigenic DriftTreating Influenza Infection, From Now and Into the FutureAntiviral resistance markers in influenza virus sequences in Mexico, 2000-2017
P2860
Q27010100-3E1EFA8F-EBB1-4912-9567-6C425F4B1E0BQ28292279-375B99B5-31D0-46F3-B2DA-C626CDE2A36BQ30353294-DF399794-5363-413C-8412-A6B014EC9914Q30355434-1D39AA72-03E0-49A4-86F8-DA0C430B0340Q30370313-C74DF70D-45E6-4B5F-87CA-1E76CFEBD9DDQ30372421-F48B2C67-19AF-4EAB-85A4-2EB43BD6D55CQ30381221-9B5E676E-47B5-43B4-9A51-9D5F6A6FAC29Q30386535-6BAAED8F-9B49-483A-B168-FFEEDE5B23D1Q30396799-844B84A1-6397-4260-AEB7-2429ADDF27D6Q30410229-55C9A97D-229C-4E95-9E96-30F6D7C893D1Q30411822-796797B2-C39C-4F2E-93B8-D87B071957FBQ30411999-FA332215-4CCA-4033-ADD3-D7E99861ADB9Q30424185-25C333C9-4AA7-4255-9373-81881AF1AD98Q30427052-920A099F-AD11-4E1C-BDB5-D123B55D5970Q30428311-0E5C3A6F-B771-4E54-BAE2-03132C820670Q33574326-FA8592F3-E476-42E6-9EC0-8B4AA50FC0EEQ34070256-1802A258-534F-4A6D-83CD-437E4FB74ECCQ34405859-9746ACFA-DB97-4855-9B18-40110C235384Q34413797-55AEC6DA-01DD-477B-85B7-BD5CE9A31152Q34942905-7A9EAE01-6B0E-47A4-BB6E-247572D8E788Q35101694-8C9EBD28-7950-4E83-9458-5AE6AF092D25Q36048315-5529B3EA-5E33-4CF2-9955-AED56DFA8BD7Q37346000-AEB397DD-142C-4176-AE6E-796AAA15B5E7Q37642063-C6E53818-AD49-4F9D-876C-53A5C830BA2FQ37828538-B84D8752-680E-44BF-A755-3CEA8472321EQ38209673-24C25928-9955-4B55-BC71-71B87B7B4732Q38633113-564A7C02-A7EF-4E2C-B2BE-347351FC26B4Q39152320-0C9B74DA-4E58-4FAF-9482-88648B9DA9BAQ39838350-06D5E057-80F9-413C-93B6-FD202B4A88ECQ40201534-78B738DD-3553-4658-BC81-26207EF51367Q40372317-86D88E80-BF4D-4C75-9BE9-D0D6F3F5B1E4Q40593477-7DED6FED-DED1-4E8E-B246-8A8E6CAAF04BQ41095623-D0C9D9C1-B07D-4E6D-8B2A-0BA10888690BQ44857539-268CA648-8E04-497C-8225-864897AAA0F6Q45324524-0B1F105D-2AED-4CAB-A1FA-7379D88B04CCQ47602754-8468C29C-A648-4554-832A-A9F074A8DA3AQ47607908-5C104741-48E8-44D9-A6F4-4953EACE93CAQ57004711-F999E801-E0C6-4B0B-9A0B-37D5A4E5E2D8Q57158941-C3CA7A9A-E25A-42DC-A2A2-FEA38E726082Q57815887-749609C2-7921-43B1-9674-4B26A5758755
P2860
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@ast
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@en
type
label
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@ast
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@en
prefLabel
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@ast
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@en
P1433
P1476
Oseltamivir resistance and the ...... pathogenic influenza viruses.
@en
P2093
Jessica K Holien
Michael W Parker
P2860
P304
P356
10.2165/11531450-000000000-00000
P577
2009-01-01T00:00:00Z
P5875
P6179
1011801843